Aimovig (erenumab-aooe) is a calcitonin gene-related peptide (CGRP) receptor antagonist, specifically indicated for the preventative treatment of migraine in adults.

Aimovig is supplied as an injection for subcutaneous use. The recommended dosage of Aimovig is 70 mg injected subcutaneously once monthly. Some patients may benefit from a dosage of 140mg injected subcutaneously once monthly, which is administered as two consecutive subcutaneous injections of 70mg each. If a dose of Aimovig is missed, administer as soon as possible. Thereafter, Aimovig can be scheduled monthly from the date of the last dose.

The most common side effects of Aimovig include: pain, redness, or swelling at the injection site and constipation.